The PMPRB has extended the deadline for comments on the revised draft Guidelines to August 4, 2020.
See here for further details on the change. Please also see our June 23, 2020 article for a summary of notable changes in the revised draft Guidelines.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
CDA releases strategy to improve the appropriate prescribing and use of prescription medications in Canada
On September 18, 2025, Canada’s Drug Agency (CDA) launched its new strategy to improve the appropriate prescribing and use of prescription medications in Canada.Read More -
PMPRB releases Annual Public Drug Plan Expenditure Report (2022/23)
On October 21, 2025, the Patented Medicine Prices Review Board (PMPRB) announced the release of CompassRx, an annual report that analyzes factors driving prescription drug expenditures in Canadian pub...Read More -
Ontario pilot program and pCPA new negotiation pathway aim to expedite access to breakthrough cancer treatments
The Ontario government and the pan-Canadian Pharmaceutical Alliance (pCPA) announced separate initiatives in October 2025, both aimed to accelerate patient access to breakthrough cancer treatments app...Read More
